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Background: There is limited data on the natural history of autoimmune hepatitis (AIH) 
and on the long-term follow-up of AIH patients who have been referred for regular medi-
cal attention.
Objectives: We evaluated the clinical presentation and natural history of AIH in a large 
cohort of type I AIH patients from Iran.
Patients and Methods: Between 1997 and 2008, 102 patients were enrolled in the study. 
Patients were diagnosed using the International Autoimmune Hepatitis Group criteria 
and were followed up for an average of 60 months. Clinical and biochemical data were 
gathered from all the patients at both the beginning and the end of the follow-up period. 
Liver biopsy was performed in all patients before treatment, and the biopsies were per-
formed in 28 patients after treatment. 
Results: Biochemical remission was achieved by 80 (79.4%) patients. Of these, 53 (66.5%) 
showed near-normal liver histology or liver function test results and sonogram. The re-
maining 27 (33.5%) patients also achieved clinical and biochemical remission, but devel-
oped compensated cirrhosis. After a period of remission, 24 patients (32.5%) relapsed. 
Among the 22 (21.6%) patients who showed ultimate treatment failure, 6 underwent or-
thotopic liver transplantation and 3 died of liver failure while awaiting a transplant. Six-
teen (72.7%) of the 22 patients who did not respond to therapy were non-compliant with 
medications and had irregular follow-up. The overall 10-year survival rate in the cohort 
was 96%.
Conclusions: Long-term survival in AIH patients is very good. Prompt diagnosis and ap-
propriate ﬁrst-line and salvage therapy that includes close follow-up will make liver 
transplantation a rare necessity in the treatment of this disease.
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 Implication for health policy/practice/research/medical education:
Data on long-term prognosis of AIH in Iranian patients in large scale are inadequate. The current study has been done on 102 pa-
tients for a mean duration of 60 months and the results highlight the favorable prognosis if certain strategies are adopted includ-
ing early diagnosis, close follow-up, and enhancing patients’ adherence to treatment. The results of this study can help clinicians 
in their practice and can guide instructors in the education they provide to gastroenterology fellows.
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1. Background
Autoimmune hepatitis (AIH) is a progressive disease of 
unknown cause that is characterized by chronic hepa-
titis, abnormal liver enzyme levels, high serum gamma 
globulin levels, and circulating autoantibodies (1, 2). It 
is more common in women than in men (sex ratio, 3.6:1) 
and is found in all age and ethnic groups (1, 2). There are 
no epidemiological data on the incidence and prevalence 
of AIH in Iran and other Middle Eastern countries, but 
an annual incidence of 2 per 100,000 and a point preva-
lence of 15 per 10,000 persons have been reported in the 
Caucasian populations of Northern European countries 
(1, 2). The uncontrolled immune response in AIH patients 
is associated with a decrease in the number and function 
of T-regulatory cells, resulting in immune intolerance 
and emergence of liver-targeted autoimmunity. This 
leads to a progressive necroinﬂammatory and ﬁbrotic 
process in the liver (2, 3). Two major forms of AIH, type 
1 and type 2, have been described on the basis of their 
autoantibody proﬁles (4). Overlap syndromes with pri-
mary sclerosing cholangitis (PSC) or primary biliary cir-
rhosis (PBC) also occur (4). The diagnosis of AIH is based 
on clinical, histopathological, and paraclinical ﬁndings. 
The International Autoimmune Hepatitis Group (IAIHG) 
has recently suggested revised criteria for use in research 
and simpliﬁed criteria for clinical use (5-7). The AIH mor-
tality rate is 80% in untreated patients (1). Prednisolone, 
alone or in combination with azathioprine, is the stan-
dard treatment. The treatment prolongs survival and im-
proves clinical, biochemical, and histological features in 
65% to 80% of patients (1, 2). Recent studies show that the 
10-year survival rate among treated patients may exceed 
90%, which is almost identical to that in an age- and sex-
matched control population (8). However, the 20-year 
survival rate may be less than 80% among patients with-
out cirrhosis and less than 40% among those with cirrho-
sis at presentation (9). The reversibility of ﬁbrosis and 
even cirrhosis in AIH has been recently conﬁrmed in sev-
eral studies (10-13). Given the gap in our current knowl-
edge on long-term patient outcomes and the course of 
the disease, long-term study of a large number of pa-
tients can give us a better understanding of the disease. 
Herein, we report the long-term outcome in AIH patients 
after ﬁrst receiving medical attention for the disease. We 
also report the nature and rate of clinical, biochemical, 
and histological responses to treatment and their deter-
minants in a large cohort of AIH patients.
2. Objectives
We evaluated the clinical presentation and the natu-
ral history of AIH in a large cohort of type I AIH patients 
from Iran.
3. Patients and Methods
All AIH patients who were referred to the outpatient 
Clinic of the Digestive Disease Research Center (DDRC) of 
Tehran University of Medical Sciences from 1997 to 2008 
were enrolled in this study. Baseline evaluation included 
a complete history and physical examination, complete 
blood count (CBC), and a comprehensive biochemical 
and serological proﬁle, including aspartate aminotrans-
ferase (AST), alanine aminotransferase (ALT), alkaline 
phosphatase (ALP), serum gamma-glutamyl transferase 
(GGT), serum γ-globulin (GGB), serum albumin, total 
protein, total and direct bilirubin, erythrocyte sedimen-
tation rate (ESR), prothrombin time, serum creatinine 
and blood urea nitrogen. Patients were also evaluated 
for chronic viral hepatitis, Wilson’s disease, α-1 antitryp-
sin deﬁciency, and hemochromatosis by using HBsAg, 
HBcAb, HBsAb, HCV Ab, serum ceruloplasmin, protein 
electrophoresis, serum iron, and total iron-binding ca-
pacity. Diagnosis of AIH was made according to the cri-
teria for the diagnosis of AIH devised in 1993 (5) and its 
revised version (6). In brief, AIH was diagnosed if patients 
had chronically elevated aminotransferases and gamma 
globulins, with positive antinuclear antibody (ANA), anti-
smooth muscle antibody (SMA), or anti-liver–kidney mi-
crosomal antibody (LKM-1) type 1, and histopathological 
features compatible with autoimmune hepatitis on liver 
biopsy. Patients were only diagnosed with AIH if they did 
not have viral (hepatitis B and C), metabolic (Wilson’s dis-
ease, α-1 antitrypsin deﬁciency, hemochromatosis), and 
drug-induced liver disease (including alcohol). Autoan-
tibodies were tested by indirect immunoﬂuorescence. A 
titer of ≥ 1 : 40 was considered to be positive. HBsAg was 
determined by Enzyme-Linked Immunosorbent Assay 
(ELISA; Stat Fax, Awareness Technology Inc., Palm City, FL, 
USA) using commercially available kits and anti-HCV Ab 
was assayed using a third generation ELISA test (Ortho-
Clinical Diagnostics, Amersham, UK). 
Percutaneous liver biopsy was performed for all pa-
tients at baseline and for 28 patients who consented to 
a second biopsy at the end of treatment. Specimens were 
ﬁxed in 10% formalin; embedded in paraﬃn; and stained 
with hematoxylin and eosin, Masson’s trichrome, and re-
ticulin. All specimens were evaluated by a single patholo-
gist. Liver biopsies were considered adequate if there 
were at least 6 portal tracts per high-power ﬁeld. Speci-
mens were scored using the modiﬁed Hepatitis Activity 
Index, in which necroinﬂammation is graded from 0 to 
18 and ﬁbrosis from 0 to 6 (14). Cirrhosis was deﬁned by 
histology or clinical imaging and laboratory ﬁndings of 
splenomegaly, esophageal varices, ascites, and low plate-
let counts. Decompensated cirrhosis was deﬁned as the 
presence of prolonged prothrombin time, emaciation, 
intractable ascites, and encephalopathy attack. Treat-
ment was started with prednisolone (30 – 50 mg/day). The 
corticosteroid was then tapered according to patients’ 
clinical and biochemical response. Treatment continued 
with the addition of 50 mg azathioprine when the pred-
nisolone dose reached 30 mg. The azathioprine dose was 
increased to 2 mg/kg body weight when the prednisolone 
dose decreased to 10 mg. Patients were then maintained 94 Hepat Mon. 2012;12(2):92-99
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on azathioprine, at a dose determined by their biochemi-
cal liver proﬁles and CBCs. If patients were intolerant to 
azathioprine for any reason, they were maintained on 
low-dose (5–10 g) prednisolone. Calcium and vitamin D3 
supplements were administered to all subjects. Patients 
who could not tolerate or did not respond to predniso-
lone for induction therapy were switched to low-dose cy-
closporine (3 mg/kg body weight per day, orally) for 6–12 
months. Dose adjustments were made to maintain the 
cyclosporine trough level at 100–300 ng/ml. Cyclospo-
rine was then tapered oﬀ and azathioprine maintenance 
instituted as described above. Ursodeoxycholic acid 
(UDCA) was added for all patients with overlap AIH/PBC 
or AIH/PSC and for patients with elevated ALP or GGT that 
was more than 2 times the normal concentration, despite 
normalization of transaminases for immunosuppressive 
therapy. Patients with advanced decompensated inactive 
cirrhosis were not enrolled in this study and were sent 
for liver transplant evaluation. Patients with postmeno-
pausal severe osteopenia, emotional instability, poorly 
controlled hypertension, and brittle diabetes were treat-
ed with cyclosporine instead of prednisolone for induc-
tion therapy. Azathioprine was avoided in patients with 
severe pretreatment cytopenia (white blood cell counts 
below 2500 or platelet counts below 50000) or who de-
veloped cytopenia during therapy. Patients underwent 
clinical and biochemical examinations every 6 weeks 
during the ﬁrst 6 months of treatment and every 4 to 6 
months after remission. Serum albumin, AST, ALT, ALP, to-
tal bilirubin, CBC, and prothrombin time were measured 
at every visit. An abdominal ultrasound examination 
was performed at regular intervals for all subjects. Dur-
ing each follow up visit, compliance, response to treat-
ment, and possible drug side eﬀects were recorded. Any 
complication or major events including esophageal or 
gastric varices, upper gastrointestinal bleeding, ascites, 
spontaneous bacterial peritonitis, and encephalopathy 
were also recorded. Complete remission was deﬁned as 
disappearance of symptoms and normalization of se-
rum ALT, AST (to equal or less than 30 IU/L), total biliru-
bin, and immunoglobulin levels with minimal activity in 
the follow-up liver biopsy (when applicable). Incomplete 
response was deﬁned as a decrease in the level of liver en-
zymes by more than half of that observed at the baseline, 
but that was never less than twice the upper normal lim-
it. Treatment failure was deﬁned as development of clini-
cal complications (i.e., development of ascites, jaundice 
or hepatic encephalopathy) laboratory deterioration or 
< 50% decrease in liver enzymes during therapy. Relapse 
was deﬁned as a rise in serum liver enzymes greater than 
three-fold the upper normal limit after remission with or 
without active disease in histology or the reappearance 
of symptoms. 
Continuous variables were expressed as mean and stan-
dard deviation (SD) values  Dichotomous variables were 
compared using chi-square tests. P value < 0.05 were con-
sidered signiﬁcant. Paired t tests were used to compare 
variables before and after treatment. Correlations be-
tween quantitative variables and the stage of ﬁbrosis at 
presentation were assessed using Spearman correlation 
coeﬃcients. Logistic regression analysis was then used to 
assess the independent association of various variables 
with the absence of ﬁbrosis in both the ﬁrst biopsy, per-
formed at presentation, and in the biopsy performed 
after treatment. Statistical analysis was performed us-
ing SPSS, version 16.0 (SPSS, Inc., Chicago, IL). The study 
protocol was approved by the Ethics Committee of the 
Digestive Disease Research Center (DDRC), and informed 
consent was obtained from all patients prior to enroll-
ment in the study.
4. Results
Among the 102 patients enrolled in this study, 35 and 
67 fulﬁlled IAIHG pre-therapy criteria for deﬁnite and 
probable AIH, respectively. One patient had both AIH and 
hepatitis C. Twenty-seven patients (26.4%) had overlap 
syndrome, of whom 19 (18.6%) had AIH/PBC and 8 (7.8%) 
had AIH/PSC. Seventy-ﬁve patients (73.5%) were women. 
Women comprised 76.0%, 84.2%, and 25.0% of AIH, AIH/
PBC, and AIH/PSC patients, respectively (AIH vs. AIH/
PSC P = 0.004, and AIH/PBC vs. AIH/PSC P < 0.001). The 
mean age was 29.1 ± 15.3 years at the time of disease on-
set and 29.6 ± 15.1 years at the time of diagnosis (range, 
3–63 years). Thirty-three patients (32.3%) were older than 
40 years and 5 (4.9%) were younger than 10 years. The age 
distribution showed 2 peaks: one among 11–20 year-old 
patients and the other among 41–45 year-old patients. 
There was no diﬀerence in the mean age of patients with 
the 3 diagnostic categories of AIH. Forty-two patients 
(41.3%) had histologic cirrhosis (stage 5 or 6) at presen-
tation. Acute presentation was observed in 43 patients 
(42.2%) and was deﬁned as the presence of recent onset 
(< 30 days) symptoms (jaundice and/or drowsiness), in 
conjunction with ALT levels higher than 10 times the up-
per normal limit and elevated prothrombin time (> 15 
s). AIH patients and patients with overlap syndrome did 
not diﬀer in their response to treatment or progression 
to cirrhosis. The most common symptoms in descending 
order were as follows: jaundice (73%), fatigue (66%), ab-
dominal pain (23%), pruritis (20%), arthralgia (16%), fever 
(14%), and weight loss (3%). At the time of physical exami-
nation, splenomegaly and ascites were detected in 58.4% 
and 16.9% of the patients, respectively.  Sixteen women 
(21.3%) reported menstrual abnormalities. One patient 
was seropositive for anti-HCV antibodies with very low 
titers of HCV RNA (HCV-RNA = 250 copy / l). Ninety pa-
tients (88.2%) were seropositive for ANA and/or SMA and 
1 patient showed anti-LKM-1 antibodies (type II AIH). ANA 
was the most frequent autoantibody detected (50.0%). 
Thirty-eight patients (39.5%) had other autoimmune con-
ditions in addition to AIH. The most frequent condition 
was thyroiditis (16%), followed by diabetes (10%), ulcer-
ative colitis (9%), and rheumatoid arthritis (3%). Baseline 
demographic, biochemical, and histological data are 95 Hepat Mon. 2012;12(2):92-99
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presented in (Table 1). In the pre-treatment liver biopsies, 
we found no ﬁbrosis (stage 0) in 1 patient (0.9%), portal 
ﬁbrotic expansion (stage 1-2) in 13 patients (12.7%), bridg-
ing ﬁbrosis (stage 3-4) in 46 patients (45.1%), and cirrhosis 
(stage 5-6) in 42 patients (41.3%). Cirrhotic patients were, 
on an average, approximately 6 years younger than non-
cirrhotic patients (P = 0.047). Patients younger than 20 
years of age were more likely to be cirrhotic at presenta-
tion than those older than 45 years of age (70.5% vs. 46.6%, 
P = 0.016). Serum γ–globulin and PT were signiﬁcantly 
higher in cirrhotic patients than in non-cirrhotic pa-
tients (P = 0.002 and P = 0.019, respectively). No other de-
mographic, baseline clinical, or biochemical data were 
associated with histological ﬁbrosis or cirrhosis at pre-
sentation. We detected cirrhosis in the baseline biopsies 
of 37 patients who presented with splenomegaly (61.6%).
Mean duration of follow-up was 60.0 ± 38.4 months 
(range, 12–144 months). Follow-up was regular in 71 pa-
tients (69.6%) and irregular in 31 (30.4%). Overall, 80 pa-
tients achieved remission (79.4%) and 22 (21.6%) either 
responded partially or did not respond to treatment. 
Among the 80 patients who achieved remission, 27 (33.7%) 
developed stable and well-compensated cirrhosis while 
Overall Cirrhotic Non-Cirrhotic P value b
Female, No. (%) 75 (73.5) 42 (72.4) 33 (75.0) 0.77 c
Age at presentation, y 29.1 ± 15.3 26.5 ± 15.2 32.5 ± 14.8 0.049
AST a, IU/L 524.9 ± 428.9 540.0 ± 414.4 513.9 ± 442.6 0.77
ALT a, IU/L 552.8 ± 480.1 605.9 ± 481.5 514.7 ± 479.7 0.36
Alkaline phosphatase, IU/L 441.7 ± 285.4 444.8 ± 300.1 439.3 ± 276.6 0.93
Serum γ –globulin, g/dL 255.4 ± 219.6 367.6 ± 252.3 172.3 ± 148.1 0.002
Total bilirubin, mg/dL 5.8 ± 6.8 7.4 ± 8.4 4.6 ± 4.9 0.06
Direct bilirubin, mg/dL 3.7 ± 4.6 4.9 ± 5.7 2.7 ± 3.2 0.02
Total protein, g/dL 8.2 ± 1.3 8.0 ± 1.4 8.4 ± 1.1 0.32
Albumin, g/dL 2.5 ± 1.5 2.3 ± 1.5  2.9 ± 1.6 0.08
White blood cell, No./mm3 7628 ± 3682 8682 ± 4458 6848 ± 2781 0.06
Hemoglobin, g/dL 12.6 ± 1.8 12.6 ± 1.9 12.8 ± 1.6 0.65
ESR a 37.2 ± 31.0 33.1 ± 31.6 42.3 ± 30.1 0.22
Platelet count (× 1000), No./mm3 199.5 ± 111.0 183.9 ± 121.4 220.7 ± 92.5 0.14
Prothrombin time, s 15.6 ± 3.7 16.1 ± 2.9 14.9 ± 4.6 0.16
INR a 1.7 ± 0.9 1.8 ± 0.8 1.5 ± 1.2 0.28
Blood urea nitrogen, mg/dL 14.1 ± 7.3 15.0 ± 8.4 13.3 ± 6.4 0.45
Creatinine, mg/dL 0.8 ± 0.4 0.9 ± 0.6 0.7 ± 0.3 0.09
HAI a 12.7 ± 3.9 14.5 ± 3.1 10.9 ± 3.9 < 0.001
Grade 9.1 ± 3.1 9.8 ± 2.8 8.4 ± 3.4 0.049
Stage 3.9 ± 1.3 4.8 ± 0.9 2.9 ± 1.0 < 0.001
Table 1. Baseline Demographic, Biochemical, and Histological Data for 102 Patients With Autoimmune Hepatitis. All values are Mean ± SD, otherwise 
noted.
aAbbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; ESR, erythrocyte sedimentation rate; HAI, hepatitis activity index; INR, 
international normalized ratio
b P value calculated using t test
c P value calculate using chi square test
Final Outcome Patients, No. (%)
Complete remission  53 (52.0)
Compensated cirrhosis 27 (26.5)
Treatment failure (decompensated cirrhosis) 13 (12.7)
Liver transplantation  6 (5.9) 
Death 3 (2.9)
Total 102 (100)
Tabulation. Final Outcome for 102 Autoimmune Hepatitis Patients at 
the End of the Follow-Up Period (Mean 5 Years)
Correlation 
Coeﬃcient
P value b
Inﬂammation Improvement
Decrease in ALT a 0.50 0.03
Decrease in AST a 0.43 0.06
Fibrosis Improvement
Decrease in ALT 0.46 0.04
Decrease in AST 0.23 0.33
Table 2. Correlations Between Biochemical and Histological 
Improvement in 102 Patients With Autoimmune Hepatitis
a  Abbreviations: ALT, alanine aminotransferase; AST, aspartate 
aminotransferase 
b P value is calculated by Pearson correlation96 Hepat Mon. 2012;12(2):92-99
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in biochemical remission. Of the 22 subjects with treat-
ment failure, 6 underwent orthotopic liver transplanta-
tion and 3 died of liver failure while on the transplant list 
(Figure 1). The remaining 13 patients who did not respond 
to treatment were in the decompensated phase of cirrho-
sis and on supportive therapy while they awaited liver 
transplantation. Sixteen (72.7%) of the 22 patients who 
did not respond to therapy had irregular follow up and 
were noncompliant with their medications. The main 
reason for noncompliance was a change in facial appear-
ance following corticosteroid therapy, especially among 
younger individuals. Only 5 patients required low-dose 
prednisolone in addition to azathioprine for mainte-
nance therapy. In 22 patients (29.3%), induction therapy 
was switched to cyclosporine because of poor adherence 
and response or corticosteroid intolerance. Among these 
patients, treatment was successful in 9, ended in stable 
cirrhosis in 10, and failed in 3. Side eﬀects were mainly 
related to corticosteroids and consisted of moon face 
(33.3%), acne (27.3%), striae (18.2%), gingivitis (18.2%), hy-
pertrichosis (9.1%), and hyperglycemia (3.0%). One pa-
tient developed generalized sepsis and died. Majority of 
the patients (87%) complained of bone pain after corti-
interval between initiation of therapy and remission was 
higher in the overlap groups than in the AIH group (5.5 ± 
3.7 vs. 3.5 ± 1.8 months, respectively; P = 0.048). Of the 80 
patients who achieved remission, 24 (30.0%) had at least 
one relapse while on maintenance therapy (Figure 3). If 
normal ALT and AST levels for remission were deﬁned 
as lower than 30 IU/L in men and lower than 19 IU/L in 
women (instead of the normal upper limit provided by 
the laboratory), then 21 of those who relapsed (87.5%) had 
abnormal liver enzymes at the time of remission and 35 
of the 56 patients who did not relapse (63.6%) had abnor-
mal liver enzymes at remission (P = 0.003 and P = 0.004 
for ALT and AST, respectively). Mean interval between 
remission and the ﬁrst relapse was 27.1 ± 15.6 months. 
Gender did not aﬀect remission rate, but patients who 
achieved remission were, on an average, older than those 
who did not respond to treatment (31.3 ± 15.5 vs. 21.0 ± 11.3 
years, respectively; P = 0.005). None of the demographic, 
clinical or biochemical variables (other than AST and 
ALT) at the time of remission predicted relapse. A second  Figure 1. Ten-Year Survival Curve for 102 Autoimmune Hepatitis Patients
Figure 3. Time Course of Relapse Among Patients Who Responded to Re-
mission Induction
costeroid therapy. The main side eﬀect of azathioprine 
was a reduction in white blood cell and platelet counts. 
This occurred in 5.8% of the patients and was managed 
by decreasing the dose or switching to corticosteroid 
maintenance. All patients tolerated the low dose of cy-
closporine very well, with occasional side eﬀects such 
as hirsutism. There were no occurrences of major side 
eﬀects such as renal failure. The ultimate outcome of im-
munosuppressive therapy in AIH patients is summarized 
in Tabulation. The 10-year survival rate in all 102 AIH pa-
tients was 96%. The mean interval between the initiation 
of treatment and remission was 3.6 ± 2.1 months. After 3 
months of therapy, 50 patients (63.3%) achieved remis-
sion, while 24 patients (30.4%) achieved remission after 
3–6 months of treatment and 5 (6.3%) achieved remission 
after 6–12 months of treatment. One patient responded 
after 12 months of treatment (Figure 2). The mean time 
The majority of patients experienced complete remission within three 
months Of starting therapy
Figure 2. Time Course of Remission Induction in Autoimmune Hepatitis 
Patients Undergoing Treatment97 Hepat Mon. 2012;12(2):92-99
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liver biopsy was performed in 28 patients who consented 
to the procedure (18 patients treated with prednisolone, 
8 treated with cyclosporine, and 2 overlap syndrome pa-
tients receiving UDCA and prednisolone). The mean in-
terval between the 2 biopsies was 4.7 ± 2.8 years. In the 
follow-up biopsies, we found the following: no ﬁbrosis 
(stage 0) in 4 patients (14.3%), portal ﬁbrotic expansion 
(stage 1-2) in 12 patients (42.9%), bridging ﬁbrosis (stage 
3-4) in 9 patients (32.1%), and cirrhosis (stage 5-6) in 3 pa-
tients (10.7%). The mean stage score of the second biopsy 
decreased by 1.8 ± 1.0 from the mean score of the ﬁrst bi-
opsy (P = 0.002). Fibrosis scores decreased by 1–3 points in 
18 patients (64.2%), did not change in 8 patients (28.6%), 
and worsened by 1 point in 2 patients (7.1%). Among the 
18 patients in whom ﬁbrosis decreased, 12 had a 1-point 
improvement, 4 had a 2-point improvement, and 2 had 
a 3-point improvement. In 8 of the 10 patients who were 
cirrhotic at presentation and underwent post-treatment 
biopsy, ﬁbrosis decreased by 1–3 points. Fibrosis did not 
get worse in any of the non-cirrhotic patients. In both 
overlap syndrome patients who underwent a second bi-
opsy, the ﬁbrosis score was worse for the second biopsy 
than for the ﬁrst biopsy. The ﬁrst of these patients had 
AIH/PBC and the ﬁbrosis score increased from 1 to 2. The 
second patient had AIH/PSC, and the ﬁbrosis score in-
creased from 2 to 4 over the course of treatment. Treat-
ment failed in both cases. Mean inﬂammation score 
decreased by 2.6 ± 3.7 points after treatment. Inﬂamma-
tion improved in 17 patients (60.7%), did not change in 
7 patients (25%), and worsened in 4 patients (14.3%). The 
mean decrease in the grade of inﬂammation among 
those who improved was 5.1 ± 2.5 points. All 18 patients 
(100%) who experienced regression of ﬁbrosis, showed 
at least 2-point improvement in their hepatic inﬂamma-
tory score, while only 1 of the 10 patients (10%) with no 
improvement in ﬁbrosis showed an improved inﬂam-
matory score (1-point improvement; P < 0.001). The mean 
inﬂammatory grade decreased by 4.6 ± 3.1 points for pa-
tients with improved ﬁbrosis after treatment, while the 
mean inﬂammatory grade increased by 0.6 ± 3.1 points 
for patients with no ﬁbrosis improvement (P < 0.001). 
Both inﬂammation and ﬁbrosis correlated with ALT lev-
els but not with AST levels (Table 2). According to univari-
ate analysis, the 8 AIH patients treated with cyclosporine 
showed more ﬁbrosis improvement between their ﬁrst 
and second biopsy than the 18 patients treated with 
prednisolone (P = 0.023). In addition, patients who ex-
perienced improved ﬁbrosis had a mean interval of 68.4 
months between the ﬁrst and last biopsies, while those 
who did not experience improved ﬁbrosis had a mean in-
terval of 32.4 months between biopsies (P = 0.005). When 
examined using multivariate logistic regression, how-
ever, the only variable associated with improved ﬁbrosis 
regression was a longer interval between the 2 biopsies 
(OR = 2.15, 95% CI: 1.11-4.16, P = 0.023). None of the demo-
graphic, baseline clinical, or biochemical data before or 
after treatment was signiﬁcantly associated with histo-
logical ﬁbrosis or cirrhosis after treatment.
5. Discussion 
Several characteristics of our patients were quite simi-
lar to those of AIH patients in other case series reports. 
These characteristics include the bimodal age distribu-
tion of patients at presentation; clinical, biochemical, 
and histopathological ﬁndings at presentation; pres-
ence of concurrent autoimmune diseases; and response 
to corticosteroids (15). Twenty-seven patients (26.4%) in 
our study had overlap syndrome, and AIH/PBC was more 
common among the patients in our study than in those 
of other reported series. In our study, 17% of the patients 
had AIH/PBC and 8% had AIH/PSC , while in Japan only 
2% of AIH patients had PBC (16) and in an Indian study 
only 1 patient (1.1%) had overlap syndrome (17). In our 
study, 42 patients (41.3%) were cirrhotic at presentation; 
this ﬁnding is similar to that of previous reports (8, 18). 
Serum γ–globulin and PT were signiﬁcantly higher in cir-
rhotic patients than in non-cirrhotic patients. Moreover, 
the cirrhotic patients were generally younger than the 
non-cirrhotic patients. As in previous studies, none of 
the baseline demographic or biochemical parameters 
examined by us predicted ﬁbrosis or cirrhosis at pre-
sentation (16, 18). Overall, 78.4% of the patients achieved 
initial remission. As in previous studies, the majority of 
the patients who responded to treatment (94%) did so 
within 6 months (8). During maintenance therapy, 30% 
of the patients had at least one relapse. Cirrhosis at pre-
sentation did not aﬀect treatment outcome. Majority of 
the patients tolerated prednisolone and azathioprine 
very well, and those who were intolerant or non-respon-
sive responded to and tolerated low dose of cyclosporine 
very well. Therefore, low dose of cyclosporine can be 
used as an alternative to corticosteroids for induction 
of remission in problematic AIH patients, especially in 
young women and patients with osteoporosis. Using 
multivariate logistic regression, only platelet count and 
PT were recognized as independent predictors of non-
response to treatment. This ﬁnding is similar to that ob-
served in our previous study (11). Therefore, AIH patients 
with a persistently low platelet count and prolonged PT 
in spite of therapy need to be counseled appropriately 
about the likely outcomes of their disease and the pos-
sible need for future liver transplantation. Our data also 
show that ﬁbrosis improves at a slow pace and follow-up 
biopsies at short time intervals may be misleading in 
this regard. Our data conﬁrms that AIH responds prom-
isingly to appropriate immunosuppressive therapy. The 
patients in our study showed a 10-year survival rate of 
96%; this rate is comparable to that observed in age- and 
sex- matched control populations (8). This high survival 
rate was achieved despite the fact that 41% of the pa-
tients were cirrhotic at presentation. The main reason 
for treatment failure was poor adherence to induction 
therapy because of changes in the facial appearance of 
young subjects who are still in school or college or are 98 Hepat Mon. 2012;12(2):92-99
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planning to marry who found their facial appearance to 
be embarrassing and unacceptable. Alternatives to high-
dose corticosteroids may help improve compliance. 
Considering its safety proﬁle, our data, and the data of 
others, low-dose cylosporine may be a good candidate 
(19). We recently completed a randomized controlled 
head-to-head comparison of low-dose cyclosporine with 
prednisolone for AIH induction therapy and found that 
low-dose cyclosporine is as eﬀective as prednisolone, 
but less toxic (20). In addition to cyclosporine, other cal-
cineurin inhibitors like tacrolimus (21, 22) and purine 
antagonists like mycophenolate mofetil (21) have been 
used successfully to treat corticosteroid-resistant AIH 
patients. In a randomized controlled trial, budesonide 
has recently been shown to be as eﬀective as predniso-
lone, with fewer side eﬀects (23). Although induction of 
remission was successful in a substantial percentage of 
patients, relapse was quite common, ranging from 30% 
after 6 months to 70% after 2–3 years of follow-up (24, 25). 
An important ﬁnding in our study was that decreasing 
AST/ALT levels to less than 30 IU/L for men and less than 
19 IU/L for women (instead of reducing AST/ALT levels to 
less than twice the normal value reported by the labo-
ratory) lessened the risk of relapse. Other investigators 
have also reported this phenomenon (18, 26). Long-term 
continuation of maintenance therapy for those in remis-
sion can also prevent relapse (18, 26). In conclusion, wise 
use of current treatment methods for AIH will help most 
patients. The main reason for rapid disease progression, 
liver failure, and cirrhosis in AIH patients is unsuitable/
deferred therapy or noncompliance with the prescribed 
therapeutic regimen. Multiple strategies may be consid-
ered to improve outcomes for AIH patients, including 
early diagnosis, targeting AST and ALT values below 30 
IU/L for men and 19 IU/L for women, early identiﬁcation 
of problematic patients, and close follow-up to ﬁnd and 
promptly treat patients who experience relapse.
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